OPKO Health and Entera Bio, a developer of oral peptides and protein replacement therapies, entered into a license agreement ...

The device, dubbed NPM-115, is a miniature sub-dermal implant that delivers exenatide, a glucagon-like peptide-1 receptor agonist (GLP-1RA). Image credit: Shutterstock / Formatoriginal. A day after ...

The safety and efficacy study recruited 32 healthy adults ranging in body weight from healthy weight to overweight. Credit: Shutterstock / leolintang. Bloom Science’s trial examining its primary ...

Florence Welch of “Florence & The Machines” sings in the song “Moderation,” “Want me to love you in moderation/Do I look moderate to you?” The British songstress illustrates a person confronting an ...

It is midday in Nairobi's Central Business District. I stroll downtown to see how easy it is to buy Ozempic, a drug sold in the Kenyan market as semaglutide and approved for diabetes but that is ...

The use of anti-obesity medications (AOMs), led by glucagon-like peptide-1 (GLP-1) agonists like Ozempic (semaglutide), has skyrocketed over the past few years. These powerful drugs, prescribed for ...

Magic bullet, miracle weight loss. Consumers continually seek quick, easy solutions to dropping excess weight. Today, there’s no denying the popularity of the next weight loss trend: anti-obesity ...

Glucagon-like peptide-1 (GLP-1) receptor agonists, or GLP-1 drugs, have quickly risen to popularity. They are already shaping food trends in major ways. But this could be only the beginning. The drugs ...

GlobalData estimates that the obesity market will be worth over $173.5bn in 2031. Credit: Deepak Verma via Getty Images. AbbVie is entering the obesity treatment market with a $2.3bn licensing ...